Product Description
Mechanisms of Action: TNFSF11 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Mabwell Therapeutics
Company Location: Asia Pacific
Company Founding Year: 2017
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Osteoporosis, Postmenopausal
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06804590 |
9MW0311-2024-CP302 | P3 |
Recruiting |
Osteoporosis, Postmenopausal |
2026-04-30 |
21% |
2025-02-07 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/05/2025 |
News Article |
Mabwell Secures Pakistan's First Denosumab Injection Approval |
